Real-world genomic profiling of solid tumors: validation and clinical insights from a Brazilian cohort.
Summary
This study details the analytical validation of the Illumina TruSight Oncology 500 (TSO500) assay within a CAP-certified clinical laboratory in Brazil. It also presents real-world findings from Comprehensive Genomic Profiling (CGP) performed on 454 patients with solid tumors. The research highlighted the genomic landscape of these tumors, including the detection of both novel and canonical gene fusions. The analytical performance of the assay was assessed, demonstrating high specificity and positive predictive value. The authors conclude that TSO500 provides crucial insights for diagnosis, prognosis, and treatment decisions in oncology.
Analysis
🔴 CLINICAL: This retrospective cohort study validates the use of the TSO500 assay in a real-world clinical setting in Brazil, strengthening precision medicine for solid tumor patients. The genomic profiling results, including gene fusion detection, can guide decisions regarding targeted therapies, potentially improving treatment strategies and patient outcomes. The integration of this assay into clinical practice could have a short-term impact (1-3 years) by providing actionable molecular information for oncologists. 🟢 BIOMOL: The study validated the TSO500 assay, a next-generation sequencing (NGS) technology utilizing Illumina NextSeq, for comprehensive genomic profiling of solid tumors. Analytical performance metrics showed a specificity of 93.39% and a positive predictive value of 73.36%, confirming its validity for variant detection. The discovery of gene fusions, including novel events, in 13% of cases, highlights the assay's capability to identify potentially relevant biomarkers for translational research and targeted therapy development. Tumor samples were used, which is standard for this type of analysis. 🔵 BIOINFO: Bioinformatics processing was performed using an in-house pipeline for alignment, variant calling, and annotation. Variant classification followed the Variant Interpretation for Cancer Consortium guidelines, ensuring standardized and robust interpretation. While the pipeline's architectural details are not described, the use of an in-house pipeline suggests customization for the laboratory's needs. Clinical deployment of this assay involves integrating the bioinformatics workflow for rapid and reliable variant report generation, facilitating molecular tumor board (MTB) meetings.